NeuroVoices: James Berry, MD, MPH, on Answer ALS’s Expanded Data Campaign
The director of the Massachusetts General Hospital ALS Care Center sat down to discuss ‘The Data is Here’ campaign from Answer ALS, the world’s largest open-sourced ALS data portal.
Phase 4 RESPOND Trial and the Need for Similar Trials in SMA: Julie Parsons, MD
The primary investigator of RESPOND discussed the trial’s goals and measures, as well as insight into why clinical trials like it are important in spinal muscular atrophy.
Transcranial Magnetic Stimulation Accurately Differentiates Dementias
Researchers developed and trained a random forest classifier that resulted in high precision and accuracy as a screening tool for those with mild cognitive impairment.
More Severe Cognitive, Physical Phenotypes Observed in Progressive Multiple Sclerosis
Researchers sought to redefine dichotomous classifications of MS and identified meaningful classifications.
Cognitive Risks Correlated With Lack of Sleep: Christian Agudelo, MD
The Evelyn F. McKnight Neurocognitive Scholar at the University of Miami Miller School of Medicine provided background on a recently completed study correlating sleep and cognitive decline.
Fumarates for Treatment of RMS
BREN-02 Wins Orphan Drug Designation for ALS
Preclinical studies have shown that the homeoprotein hEN1 is essential for the survival and maintenance of spinal cord alpha motor neurons that innervates muscles throughout the body.
Opportunities for Repurposed Drugs in ALS Clinical Trial Settings
Brian Wainger, MD, PhD, assistant professor of neurology and anesthesiology, Harvard Medical School, discussed the recently published phase 2 trial a repurposed epilepsy drug in patients with ALS.
EVT Alone Demonstrates Noninferiority to Combined Intravenous Alteplase Method
No significant between-group differences were detected in symptomatic intracerebral hemorrhage or 90-day mortality.
The Clinical Potential of the Vercise Genus DBS System
Rafael Carbunaru, PhD, MSc, vice president, research and development, Neuromodulation, Boston Scientific, discussed the system’s recent FDA approval.
Utilizing Objective Measures to Assess EEG Milestones: Fabio Nascimento, MD
The clinical fellow at Massachusetts General Hospital discussed the idea of standardizing the number of EEG reads residents should be required to do before their training is complete.
Patient’s Journey: Diagnosis of Multiple Sclerosis
FDA Approves Nerivio Migraine Device for Adolescents
After winning FDA approval in October 2020, the new expanded indication includes adolescents aged 12 and older with episodic or chronic migraine.
"Curing the Epilepsies 2021" Recap
Veronica Hood, PhD, writes a recap of research and treatments for epilepsy presented at the meeting.
This Week on NeurologyLive — January 25, 2021
Here's what is coming soon to NeurologyLive.
Patients With Schizophrenia Spectrum Disorders at Greater Risk for Later Parkinson Disease
Patients with SCD and schizophrenia specifically had increased risk of developing Parkinson disease later in life.
Resources for Patient Families from Dravet Syndrome Foundation
The Dravet Syndrome Foundation offers a list of online resources for patient families.
Restoring Function in TBI with Stem Cell Therapy: Bijan Nejadnik, MD
The chief medical officer at SanBio discussed how the investigational agent SB623 can fill the void of disease-modifying therapies for TBI.
PAME 2020: A Parent's Perspective
A parent's perspective of the Partners Against Mortality in Epilepsy (PAME) 2020 meeting.
Stanford Children’s Health: A Comprehensive Approach to Care for a Child With a Neurological Condition
Physicians from Stanford Children’s Health offer their keys to successful pediatric neuroscience teams and what to focus on to provide a better quality of life for children.
Expanding the Understanding of ALS With New Methods: Brian Wainger, MD, PhD
The assistant professor of neurology and anesthesiology at Harvard Medical School discussed non-traditional ways ALS research is changing and where the focus should continue to be.
Olfactory Impairment Can Identify Patients at Risk for Parkinson Disease
Olfactory impairment is indicative of rapid eye movement sleep behavior disorder, a prodromal symptom of Parkinson disease.
FDA Approves TBI Blood Test, Causal Link Between Smoking and Subarachnoid Hemorrhage, Inconsistencies Across EEG Education
Neurology News Network for the week ending January 23, 2021.
NeurologyLive Friday 5 — January 22, 2021
Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 22, 2021.
Evaluating Toferson for People with Pre-Symptomatic ALS
Michael Benatar, MD, PhD, executive director, ALS Center at the University of Miami, discusses collaborating with Biogen on a clinical study evalutating tofersen.
Unique Pathology of Primary Progressive Aphasia Preserves Memory
The asymmetry of mediotemporal atrophy and a lesser impact of APOE4 and TDP-43 on the integrity of memory circuitry may have constituted preservation in primary progressive aphasia.
Future Studies on Cenobamate for Epilepsy: William Rosenfeld, MD
The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, also discussed future studies planned for cenobamate.
FDA Approves Boston Scientific’s Vercise Genus DBS System for Use in MRI Environment
This fourth-generation system since 2012 is indicated as adjunctive therapy for stimulation of the subthalamic nucleus and internal globus pallidus to treat Parkinson symptoms.
FDA Accepts NDA for INP104 for Acute Migraine Treatment
If approved, INP104 would be the first and only delivery system to explore the vascular-rich upper nasal space as a therapeutically viable treatment pathway.
New Study Clarifies Gray Matter Atrophy in MS Phenotypes
Source-based morphometry, a novel independent component analysis technique, was found to be useful in characterizing patterns of atrophy development.
